Thoracic endovascular aortic repair for type B aortic dissection after renal transplantation
Metrics: PDF 454 views | HTML 882 views | ?
Chang Shu1,2, QingGen Xiong1, Jian Qiu1, MingYao Luo2 and Kun Fang2
1Department of Vascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, China
2Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
Chang Shu, email: email@example.com
Keywords: type B, aortic dissection, TEVAR, renal transplantation, follow up
Received: March 12, 2017 Accepted: July 12, 2017 Published: September 30, 2017
Thoracic endovascular repair (TEVAR) is an effective treatment for type B aortic dissection (TBAD). Here, we evaluated the early-midterm effectiveness and safety of TEVAR for treating TBAD patients after renal transplantation. Six patients with TBAD treated with TEVAR after renal transplantation were recruited between February 2012 and December 2016. They were then followed up with clinical examinations and computed tomography angiography (CTA). TEVAR was successfully performed in all patients (100%), and the primary tear sites were well covered by stents with or without coverage of the left subclavian artery. No severe complications occurred in any patient during perioperative period. The one-year survival rate was 100%, one patient died of renal graft failure and heart failure four years after TEVAR; the remaining five patients (83.3%) survived and exhibited no severe complications. Our findings show that TEVAR provides satisfactory short-midterm results for TBAD patients after renal transplantation. Moreover, our experience shows that it need relative longer proximal landing zone to prevent the endoleak and recurrence. However, regular hematodialysis, long-term immunosuppressive therapy, and blood pressure control remain crucial factors to prolong survival. Long-term follow-up studies are needed to evaluate the long-term prognosis in these patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.